The Future of Brain Health

Founded in 2024 by neurologist and health-system executive Dr. Rany Aburashed, Neurogen Biomarking was built on a clear promise: deliver expert, premium brain-health care that is accessible to everyone, and treat every family like our own. Headquartered in Chicago, with leadership and operations across the United States, the company serves three primary markets: U.S. healthcare systems, employer health networks, and proactive consumers. Neurogen's mission is to democratize early detection and management of brain health so that patients and families are no longer failed by late diagnoses. The company's early traction reflects real demand, a waitlist exceeding 1,000 individuals before formal launch, and a beta cohort of more than 500 participants reporting 98% satisfaction.

How It Works

Neurogen brings early Alzheimer's detection out of the academic lab and into daily life through a premium, end-to-end service. A simple at-home blood collection measures phosphorylated tau 217 (pTau217), one of the earliest validated biomarkers of Alzheimer's pathology. This is paired with a modern, digital cognitive assessment. Critically, results are not left to algorithms. Every participant receives a consultation with a board-certified neurologist who interprets the biomarker and cognitive findings within the broader clinical context, including comorbidities such as kidney disease, cerebrovascular history, or cardiovascular factors. The outcome is clarity and a personalized plan, delivered years earlier than traditional pathways typically provide.

What Makes Neurogen Different

Most diagnostics provide data. Neurogen delivers direction with actionable steps. The company integrates cutting-edge science, personal neurologist care, and human-centered attention into a single, accountable ecosystem designed to change outcomes, not just measure them. Partnerships with leading technology providers and collaborations with digital cognitive innovators ensure accuracy and scalability. A world-class Scientific Advisory Committee, with experts from Harvard, Wake Forest, University of Pittsburgh, Indiana University, Amsterdam UMC, and Banner Health, anchors the platform in rigorous, peer-aligned standards. Unlike offerings built primarily by business generalists, Neurogen was architected by practicing clinicians and clinical-trial leaders to trailblaze responsibly within accepted medical norms. It is not a "test in a box." It is a clinical pathway that earns trust by design.

Leadership and Governance

Leadership and Governance

Dr. Aburashed, Founder and CEO, has led more than 40 clinical trials focused on neurodegenerative biomarkers and previously served as Corporate Chief Medical Officer and Chair of Specialty Services at Insight Health Systems. He is joined by Ken Bahk, PhD, Chief Strategy Officer, a veteran of healthcare ventures and digital transformation, and Elisabeth Thijssen, PhD, Chief Scientific Officer, an internationally recognized neuroscientist in Alzheimer's biomarker research. Together, they align scientific rigor with operational scale and customer experience.

Why It Matters

Early detection changes the economic and human calculus of Alzheimer's. Identifying risk sooner opens doors to disease-modifying therapies, targeted lifestyle interventions, clinical trials, and practical planning, opportunities that narrow dramatically once decline accelerates. Neurogen's premium experience, fast access, physician-led interpretation, and clear next steps convert uncertainty into agency for patients, families, employers, and payers.

The Road Ahead

Neurogen's vision is to make proactive brain-health screening as routine as cholesterol checks. By meeting people earlier and guiding them with clinical nuance, the company aims to reset expectations for what compassionate, modern neurology looks like: measurable science, delivered accessibly, with outcomes at the center.

Learn more at Neurogenbiomarking.com.